Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem/progenitor cells (MSCs) are key players in regenerative medicine, relying principally on their differentiation/regeneration potential, immunomodulatory properties, paracrine effects, and potent homing ability with minimal if any ethical concerns. Even though multiple preclinical and clinical studies have demonstrated remarkable properties for MSCs, the clinical applicability of MSC-based therapies is still questionable. Several challenges exist that critically hinder a successful clinical translation of MSC-based therapies, including but not limited to heterogeneity of their populations, variability in their quality and quantity, donor-related factors, discrepancies in protocols for isolation, in vitro expansion and premodification, and variability in methods of cell delivery, dosing, and cell homing. Alterations of MSC viability, proliferation, properties, and/or function are also affected by various drugs and chemicals. Moreover, significant safety concerns exist due to possible teratogenic/neoplastic potential and transmission of infectious diseases. Through the current review, we aim to highlight the major challenges facing MSCs’ human clinical translation and shed light on the undergoing strategies to overcome them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527 · cited 1×
“The explant method demonstrates a more homogenous cell population, higher cell viability, and increased cell proliferation rates and avoids enzymatic damage as compared to the enzymatic method [198–200], which could be attributed to the gradual transition of cells from in vivo to in vitro condition [180, 201].”
ResultKern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 2×
“ASCs were originally described as a more convenient alternative to BMSCs [146] with less invasive isolation procedure [147], higher yield of progenitor cells [148, 149], and greater proliferation rate [145, 150].”
BackgroundMesenchymal stem cells as trophic mediators
Caplan, A. I., & Dennis, J. E. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20886 · Cited by 2,992 · cited 1×
“But if the presence of MSCs at the target site is mandatory, for example, by differentiating into replacement cells [462], or through the local production of angiogenic or antiapoptotic factors [459], then the delivery route must place the cells at the target site or facilitate their migration to the site of interest…”
BackgroundLee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., Redl, H., Rubin, J. P., Yoshimura, K., & Gimble, J. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.02.006 · Cited by 1,890
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Concise review: MSC-derived exosomes for cell-free therapy
Phinney, D. G., & Pittenger, M. F. (2017) · Stem Cells · doi:10.1002/stem.2575 · Cited by 1,834
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819 · cited 1×
“Challenges in defining an optimal cell dose for specific therapeutic applications are related to the large variabilities in MSC clinical trials, including different disease categories, study design, target tissue/organs, types of MSCs used, manufacturing protocols, routes of delivery, and dosing employed [495, 496].”
BackgroundCaplan, A. I., & Correa, D. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.008 · Cited by 1,682
Mechanical forces direct stem cell behaviour in development and regeneration
Vining, K. H., & Mooney, D. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.108 · Cited by 1,656
Mesenchymal Stem Cell Homing: The Devil Is in the Details
Karp, J. M., & Leng Teo, G. S. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.001 · Cited by 1,445 · cited 1×
“It was found that upon prolonging the MSC expansion for 43-77 days, cells demonstrated senescence features, including abnormality in morphology, arrested proliferation, decreased expression of cell surface markers, loss of differentiation capacity [220], and decrease in their capacity for migration [221].”
BackgroundFischer, U. M., Harting, M. T., Jimenez, F., Monzon-Posadas, W. O., Xue, H., Savitz, S. I., Laine, G. A., & Cox, C. S. (2009) · Stem Cells and Development · doi:10.1089/scd.2008.0253 · Cited by 1,292
Stolzing, A., Jones, E., McGonagle, D., & Scutt, A. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.12.002 · Cited by 1,195 · cited 3×
“MSCs’ quality, quantity, and characteristics rely upon a variety of donor-related factors [22], including body mass index [23, 24], age [25, 26], gender [27], and systemic and autoimmune diseases [28–30].”
BackgroundThree-Dimensional Cell Culture Matrices: State of the Art
Lee, J., Cuddihy, M. J., & Kotov, N. A. (2008) · Tissue Engineering Part B: Reviews · doi:10.1089/teb.2007.0150 · Cited by 1,047 · cited 1×
“The 3D microenvironment is responsible for determining MSC fate in vivo, where it allows interactions between MSCs, ECM, and gradients of oxygen, nutrients, and byproducts [324].”
BackgroundIn vitro Hepatic Differentiation of Human Mesenchymal Stem Cells
Lee, K., Kuo, T. K., Whang–Peng, J., Chung, Y., Lin, C., Chou, S., Chen, J., Chen, Y., & Lee, O. K. (2004) · Hepatology · doi:10.1002/hep.20469 · Cited by 865 · cited 2×
“Neural differentiation was achieved in media supplemented with both epidermal growth factor (EGF) and fibroblast growth factor- (FGF-) 2 [256, 257], while hepatic differentiation occurred in media supplemented with hepatocyte growth factor (HGF), bFGF, and oncostatin [255].”
BackgroundDecellularization Strategies for Regenerative Medicine: From Processing Techniques to Applications
Gilpin, A., & Yang, Y. (2017) · BioMed Research International · doi:10.1155/2017/9831534 · Cited by 742
Tissue Engineering and Regenerative Medicine: History, Progress, and Challenges
Berthiaume, F., Maguire, T. J., & Yarmush, M. L. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114257 · Cited by 734
Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies
Noronha, N. D. C., Mizukami, A., Caliári-Oliveira, C., Cominal, J. G., Rocha, J. L. M., Covas, D. T., Swiech, K., & Malmegrim, K. C. R. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1224-y · Cited by 623
Choudhery, M. S., Badowski, M., Muise, A., Pierce, J., & Harris, D. T. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-8 · Cited by 529 · cited 1×
“Likewise, human BMSCs and ASCs displayed an age-related increase in cellular senescence (apoptosis) and expression of p53 gene [25] in addition to a decrease in the cellular proliferation rate [25, 37] and osteogenic [25, 37–40] and chondrogenic differentiation in vitro [37, 41], with an increase in adipogenic potenti…”
BackgroundHypoxia enhances proliferation and tissue formation of human mesenchymal stem cells
Grayson, W. L., Zhao, F., Bunnell, B., & Ma, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.054 · Cited by 521
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling
Skardal, A., Shupe, T., & Atala, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.003 · Cited by 512 · cited 1×
“2D culture techniques have been developed for establishing primary cultures, cell lines, and different analytical assays [313].”
BackgroundComparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Cartilage, and Adipose Tissue
Peng, L., Jia, Z., Yin, X., Zhang, X., Liu, Y., Chen, P., Ma, K., & Zhou, C. (2008) · Stem Cells and Development · doi:10.1089/scd.2007.0217 · Cited by 368 · cited 2×
“ASCs were originally described as a more convenient alternative to BMSCs [146] with less invasive isolation procedure [147], higher yield of progenitor cells [148, 149], and greater proliferation rate [145, 150].”
BackgroundRole of mesenchymal stem cells in bone regeneration and fracture repair: a review
Wang, X., Wang, Y., Gou, W., Lu, Q., Peng, J., & Lu, S. (2013) · International Orthopaedics · doi:10.1007/s00264-013-2059-2 · Cited by 357 · cited 1×
“Several other cytokines and growth factors, including IL-1 to IL-6, PDGF, VEGF, and BMP, are secreted by platelets, inflammatory cells, and macrophages arriving at the site of injury which could promote migration of MSCs [505].”
BackgroundAdult human mesenchymal stem cell as a target for neoplastic transformation
Serakinci, N., Guldberg, P., Burns, J. S., Abdallah, B., Schrødder, H., Jensen, T., & Kassem, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207651 · Cited by 350 · cited 1×
“However, in a further study, MSCs-TERT showed loss of contact inhibition and anchorage independence and lead to tumor formation in all mice [224].”
BackgroundZheng, X., Baker, H., Hancock, W. S., Fawaz, F., McCaman, M., & Pungor, E. (2006) · Biotechnology Progress · doi:10.1021/bp060121o · Cited by 346 · cited 1×
“TGFβ was documented to inhibit the growth of mouse keratinocytes [277], while EGF was reported to inhibit human epidermoid carcinoma cells [278].”
BackgroundMesenchymal stem cells induce apoptosis of activated T cells
Plumas, J., Chaperot, L., Richard, M.-J., Molens, J.-P., Bensa, J.-C., & Favrot, M.-C. (2005) · Leukemia · doi:10.1038/sj.leu.2403871 · Cited by 326 · cited 1×
“The effect of hPL on the immunomodulatory attributes of MSCs remains controversial and needs to be further evaluated, as some researchers claimed that hPL-expanded MSCs exhibited diminished immunosuppressive properties [292, 310], while others reported that hPL maintain these immunosuppressive properties [250, 311].”
BackgroundPDGF in bone formation and regeneration: New insights into a novel mechanism involving MSCs
Caplan, A. I., & Correa, D. (2011) · Journal of Orthopaedic Research · doi:10.1002/jor.21462 · Cited by 312
Xu, L., Liu, Y., Sun, Y., Wang, B., Xiong, Y., Lin, W., Wei, Q., Wang, H., He, W., Wang, B., et al. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0716-x · Cited by 284 · cited 1×
“Unfortunately, ASCs have a strong adipogenic differentiation tendency [153, 154], in addition to decreased proangiogenic factors and cytokine secretion as compared to BMSCs [155, 156].”
BackgroundCao, J., Wang, B., Tang, T., Lv, L., Ding, Z., Li, Z., Hu, R., Wei, Q., Shen, A., Fu, Y., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01719-2 · Cited by 264 · cited 1×
“Furthermore, 3D-exosomes were efficiently captured by tubular epithelial cells, thereby improving their viability and inducing an upregulated anti-inflammatory effect in vitro [349].”
BackgroundPersistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells
Cramer, C., Freisinger, E., Jones, R. K., Slakey, D. P., Dupin, C. L., Newsome, E. R., Alt, E. U., & Izadpanah, R. (2010) · Stem Cells and Development · doi:10.1089/scd.2010.0009 · Cited by 209
Impact of genomic damage and ageing on stem cell function
Behrens, A., van Deursen, J. M., Rudolph, K. L., & Schumacher, B. (2014) · Nature Cell Biology · doi:10.1038/ncb2928 · Cited by 207
Du, W. J., Chi, Y., Yang, Z. X., Li, Z. J., Cui, J. J., Song, B. Q., Li, X., Yang, S. G., Han, Z. B., & Han, Z. C. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0418-9 · Cited by 200
Translational strategies and challenges in regenerative medicine
Dimmeler, S., Ding, S., Rando, T. A., & Trounson, A. (2014) · Nature Medicine · doi:10.1038/nm.3627 · Cited by 179
Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs
Lozito, T. P., & Tuan, R. S. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22344 · Cited by 171
Genetic Engineering of Mesenchymal Stem Cells and Its Application in Human Disease Therapy
Hodgkinson, C. P., Gomez, J. A., Mirotsou, M., & Dzau, V. J. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.165 · Cited by 150
Ryu, A. H., Eckalbar, W. L., Kreimer, A., Yosef, N., & Ahituv, N. (2017) · doi:10.1101/130484 · Cited by 139
Ryu, A. H., Eckalbar, W. L., Kreimer, A., Yosef, N., & Ahituv, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-07757-w · Cited by 139 · cited 1×
“Antibiotics or antimicrobials are commonly used to supplement culture media to avoid any bacterial contamination of the cell culture [523].”
BackgroundSalazar, K. D., Lankford, S. M., & Brody, A. R. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90347.2008 · Cited by 134
Li, A., Xia, X., Yeh, J., Kua, H., Liu, H., Mishina, Y., Hao, A., & Li, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113785 · Cited by 100 · cited 2×
“PDGF-AA was reported to promote MSC migration and osteogenic differentiation [415].”
BackgroundLiang, J., Zhang, H., Zhao, C., Wang, D., Ma, X., Zhao, S., Wang, S., Niu, L., & Sun, L. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13015 · Cited by 93 · cited 2×
“Randomized clinical trials demonstrated a potent regenerative potential of allogenic MSC administration on cardiac [101, 102, 112], hepatic [103], and cartilage [113] tissues with no adverse effects.”
BackgroundBlázquez-Prunera, A., Díez, J. M., Gajardo, R., & Grancha, S. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0552-z · Cited by 79
Kim, D. S., Lee, M. W., Lee, T.-H., Sung, K. W., Koo, H. H., & Yoo, K. H. (2017) · Biomedical Reports · doi:10.3892/br.2017.845 · Cited by 65
Cited by
The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review
Česnik, A. B., & Švajger, U. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1400347 · Cited by 128
“MSCs isolated from different sources share many common characteristics, but they also show particular phenotypic and functional differences (Patel et al., 2016; Wu et al., 2018; Rady et al., 2020a; Shin et al., 2021; Li Y. et al., 2022; Li S. et al., 2022; Laloze et al., 2023).”
BackgroundMesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
“Among them, MSCs can be successfully isolated and expanded from several common sources [188], i.”
BackgroundMinev, T., Balbuena, S., Gill, J. M., Marincola, F. M., Kesari, S., & Lin, F. (2024) · Oncotarget · doi:10.18632/oncotarget.28672 · Cited by 34
“Furthermore, the proliferative capacity of MSCs, combined with genetic modifications, raises concerns about the potential for uncontrolled cell growth and tumorigenicity [64].”
Mesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review
Wu, K.-C., Chang, Y.-H., Ding, D.-C., & Lin, S.-Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312911 · Cited by 33
“Despite these advancements, challenges persist in clinical translation, such as population heterogeneity, variability in isolation and expansion protocols, and safety concerns regarding teratogenic potential [99].”
Metadata
- Authors
- Rady, D., Abbass, M. M. S., El-Rashidy, A. A., El Moshy, S., Radwan, I. A., Dörfer, C. E., & Fawzy El-Sayed, K. M.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2020-08-11
- Volume
- 2020
- Pages
- 1-45
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W3048635192
- Cited by
- 68
- References
- 42
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.